TRDA Q3 2025 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-91.8% YoY

Gross Profit

-$37M-2276.8% margin

Operating Income

-$47M-2915.2% margin

Net Income

-$44M-2734.4% margin

EPS (Diluted)

$-1.06

QoQ Revenue Growth

-17.2%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$413M

Total Liabilities

$72M

Stockholders' Equity

$341M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$20M	-91.8%
Gross Profit	-$37M	$20M	-287.8%
Operating Income	-$47M	-$22M	-117.2%
Net Income	-$44M	-$14M	-214.5%

Revenue Segments

License

$500,000100%